Mainz Biomed N.V (NASDAQ: MYNZ) Could Soar To Much Higher Prices In Coming Months

In the latest trading session, 2.86 million Mainz Biomed N.V (NASDAQ:MYNZ) shares changed hands as the company’s beta touched 0.06. With the company’s most recent per share price at $0.20 changed hands at -$0.02 or -8.64% at last look, the market valuation stands at $11.06M. MYNZ’s current price is a discount, trading about -795.0% off its 52-week high of $1.79. The share price had its 52-week low at $0.19, which suggests the last value was 5.0% up since then. When we look at Mainz Biomed N.V’s average trading volume, we note the 10-day average is 4.37 million shares, with the 3-month average coming to 3.54 million.

Mainz Biomed N.V (NASDAQ:MYNZ) trade information

Instantly MYNZ was in red as seen in intraday trades today. With action -3.13%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -82.67%, with the 5-day performance at -3.13% in the red. However, in the 30-day time frame, Mainz Biomed N.V (NASDAQ:MYNZ) is -17.96% down. Looking at the short shares, we see there were 3.57 million shares sold at short interest cover period of 0.76 days.

Mainz Biomed N.V (MYNZ) estimates and forecasts

Data shows that the Mainz Biomed N.V share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -76.84% over the past 6 months, a 53.70% in annual growth rate that is considerably higher than the industry average of 17.70%. Year-over-year growth is forecast to reach 21.22% up from the last financial year.

Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of 200k. 1 analysts are of the opinion that Mainz Biomed N.V’s revenue for the current quarter will be 300k. The company’s revenue for the corresponding quarters a year ago was 250.1k and 248.95k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -20.03%. The estimates for the next quarter sales put growth at 20.51%. The 2024 estimates are for Mainz Biomed N.V earnings to increase by 63.58%.